PE20211644A1 - Compuestos para tratar ciertas leucemias - Google Patents
Compuestos para tratar ciertas leucemiasInfo
- Publication number
- PE20211644A1 PE20211644A1 PE2021000343A PE2021000343A PE20211644A1 PE 20211644 A1 PE20211644 A1 PE 20211644A1 PE 2021000343 A PE2021000343 A PE 2021000343A PE 2021000343 A PE2021000343 A PE 2021000343A PE 20211644 A1 PE20211644 A1 PE 20211644A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- leukemia
- protein
- compounds
- abl1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta referido a un compuesto de la formula (I) o (Ia), en donde: R1 es arilo, heteroarilo, entre otras opciones; R2 es H, alquilo, cicloalquilo, heterocicloalquilo, entre otras opciones; R3 es H, alquilo, alquenilo, alquinilo, cicloalquilo, entre otros; R4 es alquilo, alquenilo o alquinilo; L es -NH-CO-, -CO-NH-, -NH-SO2-, o -SO2-NH-; X es O, S; Y es CH, C-(alquilo C1-C2), C-halo o N; Z es CR5 o N. Estos compuestos inhiben la actividad enzimatica de tirosina quinasa de una proteina seleccionada de la proteina Abelson (ABL1), proteina relacionada con Abelson (ABL2), o una proteina quimerica BCR-ABL1, por lo que se les emplea en el tratamiento de la leucemia, principalmente la leucemia mieloide cronica (CML), leucemia mieloide aguda (AML), o leucemia linfoblastica aguda (ALL).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733029P | 2018-09-18 | 2018-09-18 | |
| US201962816637P | 2019-03-11 | 2019-03-11 | |
| US201962889929P | 2019-08-21 | 2019-08-21 | |
| PCT/US2019/051567 WO2020061086A2 (en) | 2018-09-18 | 2019-09-17 | Compounds for treating certain leukemias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211644A1 true PE20211644A1 (es) | 2021-08-24 |
Family
ID=69774840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000343A PE20211644A1 (es) | 2018-09-18 | 2019-09-17 | Compuestos para tratar ciertas leucemias |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10889571B2 (es) |
| EP (1) | EP3852745A4 (es) |
| JP (2) | JP7611832B2 (es) |
| KR (1) | KR20210061377A (es) |
| CN (3) | CN112770745B (es) |
| AU (2) | AU2019342102B2 (es) |
| BR (1) | BR112021004051A2 (es) |
| CA (1) | CA3110576A1 (es) |
| CL (1) | CL2021000637A1 (es) |
| CO (1) | CO2021004704A2 (es) |
| IL (2) | IL281427B1 (es) |
| MA (1) | MA53664A (es) |
| MX (2) | MX2021003093A (es) |
| NZ (1) | NZ773110A (es) |
| PE (1) | PE20211644A1 (es) |
| SG (1) | SG11202102367TA (es) |
| TW (1) | TWI826525B (es) |
| WO (1) | WO2020061086A2 (es) |
| ZA (1) | ZA202101304B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211644A1 (es) | 2018-09-18 | 2021-08-24 | Terns Inc | Compuestos para tratar ciertas leucemias |
| IL316875A (en) | 2018-10-05 | 2025-01-01 | Annapurna Bio Inc | Compounds and compositions for treating conditions associated with APJ receptor activity |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CA3129019A1 (en) | 2019-03-11 | 2020-09-17 | Yong Li | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
| CN112300129B (zh) * | 2019-07-29 | 2021-09-14 | 苏州亚盛药业有限公司 | 作为bcr-abl抑制剂的杂环化合物 |
| AU2020346057A1 (en) | 2019-09-12 | 2022-04-21 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| US20240059682A1 (en) * | 2021-03-03 | 2024-02-22 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CN116375650B (zh) * | 2022-12-30 | 2025-08-05 | 浙江美诺华药物化学有限公司 | 一种替戈拉生中间体的制备方法 |
| WO2025049931A1 (en) * | 2023-08-31 | 2025-03-06 | Terns Pharmaceuticals, Inc. | Combinations comprising bcr:abl-1 inhibitor and a second tyrosine kinase inhibitor for use in the treatment of cancer |
| WO2025226724A1 (en) * | 2024-04-23 | 2025-10-30 | Terns Pharmaceuticals, Inc. | Bcr-abl1 inhibitors for use in treating cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139828A0 (en) * | 1998-05-22 | 2002-02-10 | Avanir Pharmaceuticals | COMPOUNDS HAVING IgE AFFECTING PROPERTIES |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TW200716110A (en) * | 2005-04-20 | 2007-05-01 | Smithkline Beecham Corp | Inhibitors of AKT activity |
| CN101553468A (zh) * | 2006-10-18 | 2009-10-07 | 诺瓦提斯公司 | 有机化合物 |
| AR063311A1 (es) * | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| GB0800035D0 (en) | 2008-01-02 | 2008-02-13 | Glaxo Group Ltd | Compounds |
| WO2013033093A1 (en) | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| WO2013171641A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| AU2013261130A1 (en) | 2012-05-15 | 2014-10-23 | Novartis Ag | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
| MA37519B1 (fr) | 2012-05-15 | 2017-03-31 | Novartis Ag | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 |
| CA2874303C (en) | 2012-06-11 | 2020-10-13 | Ucb Biopharma Sprl | Tnf -alpha modulating benz imidazoles |
| CN103113355B (zh) | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| GB201401086D0 (en) | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US9931342B2 (en) | 2016-02-02 | 2018-04-03 | Duke University | Compositions and methods for the treatment of cancer |
| WO2017186148A1 (en) | 2016-04-29 | 2017-11-02 | Astar Biotech Llc | Novel heterocyclic compounds as tyrosine kinase bcr-abl inhibitors |
| ES2864405T3 (es) | 2017-01-20 | 2021-10-13 | Shenzhen Targetrx Inc | Compuesto de (hetero)arilamida para inhibir la actividad de proteína quinasa |
| JP6778833B2 (ja) | 2017-01-20 | 2020-11-04 | 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． | キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物 |
| WO2018191146A1 (en) * | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| US11649218B2 (en) | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
| PE20211644A1 (es) | 2018-09-18 | 2021-08-24 | Terns Inc | Compuestos para tratar ciertas leucemias |
| US20240262842A1 (en) | 2021-04-27 | 2024-08-08 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant |
| JP2024534707A (ja) | 2021-09-30 | 2024-09-20 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ４員縮合環式化合物、並びにその調製方法及び使用 |
| WO2024199447A1 (zh) | 2023-03-30 | 2024-10-03 | 江苏豪森药业集团有限公司 | 四元稠环类化合物盐晶型及其制备方法和应用 |
| WO2025049931A1 (en) | 2023-08-31 | 2025-03-06 | Terns Pharmaceuticals, Inc. | Combinations comprising bcr:abl-1 inhibitor and a second tyrosine kinase inhibitor for use in the treatment of cancer |
-
2019
- 2019-09-17 PE PE2021000343A patent/PE20211644A1/es unknown
- 2019-09-17 IL IL281427A patent/IL281427B1/en unknown
- 2019-09-17 MX MX2021003093A patent/MX2021003093A/es unknown
- 2019-09-17 KR KR1020217011001A patent/KR20210061377A/ko active Pending
- 2019-09-17 AU AU2019342102A patent/AU2019342102B2/en active Active
- 2019-09-17 SG SG11202102367TA patent/SG11202102367TA/en unknown
- 2019-09-17 CN CN201980060896.3A patent/CN112770745B/zh active Active
- 2019-09-17 JP JP2021539486A patent/JP7611832B2/ja active Active
- 2019-09-17 CN CN202210968772.9A patent/CN115215838B/zh active Active
- 2019-09-17 TW TW108133432A patent/TWI826525B/zh active
- 2019-09-17 CA CA3110576A patent/CA3110576A1/en active Pending
- 2019-09-17 WO PCT/US2019/051567 patent/WO2020061086A2/en not_active Ceased
- 2019-09-17 US US16/573,860 patent/US10889571B2/en active Active
- 2019-09-17 NZ NZ773110A patent/NZ773110A/en unknown
- 2019-09-17 CN CN202210969394.6A patent/CN115448908B/zh active Active
- 2019-09-17 BR BR112021004051-0A patent/BR112021004051A2/pt unknown
- 2019-09-17 EP EP19862388.6A patent/EP3852745A4/en active Pending
- 2019-09-17 MA MA053664A patent/MA53664A/fr unknown
-
2021
- 2021-02-25 ZA ZA2021/01304A patent/ZA202101304B/en unknown
- 2021-03-16 MX MX2023007714A patent/MX2023007714A/es unknown
- 2021-03-16 CL CL2021000637A patent/CL2021000637A1/es unknown
- 2021-04-15 CO CONC2021/0004704A patent/CO2021004704A2/es unknown
-
2023
- 2023-06-22 US US18/339,516 patent/US12240835B2/en active Active
-
2024
- 2024-12-20 AU AU2024287115A patent/AU2024287115A1/en active Pending
- 2024-12-24 JP JP2024227127A patent/JP2025066704A/ja active Pending
-
2025
- 2025-01-30 US US19/041,557 patent/US20250276961A1/en active Pending
- 2025-03-06 US US19/072,824 patent/US12454524B2/en active Active
- 2025-08-03 IL IL322515A patent/IL322515A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211644A1 (es) | Compuestos para tratar ciertas leucemias | |
| PE20210004A1 (es) | Inhibidores de mcl-1 | |
| CL2020003219A1 (es) | Compuestos | |
| EA202092248A1 (ru) | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими | |
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| MX388751B (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| MX2016003239A (es) | Pesticidas de azoles biciclicos sustituidos con heterociclos. | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20200292A1 (es) | Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats | |
| EA201992322A2 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| SA523440283B1 (ar) | مركبات مضادة للأورام | |
| NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
| CL2016002033A1 (es) | Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros. | |
| ECSP056072A (es) | Pirimidinonas sustituidas | |
| PE20180024A1 (es) | Triazolopirazinonas como inhibidores de pde1 | |
| PE20220281A1 (es) | Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos | |
| MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
| EA201892815A1 (ru) | Новые антибактериальные соединения | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| PE20200333A1 (es) | Compuestos y metodos para tratar infecciones bacterianas | |
| JOP20190073A1 (ar) | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 | |
| MD20230027A2 (ro) | Amestecuri de pesticide cu conţinut de indazoli |